Please login to the form below
irritable bowel syndrome
This page shows the latest irritable bowel syndrome news and features for those working in and with pharma, biotech and healthcare.
Ardelyx gets second kidney disease trial win for tenapanor
verdict on the use of the drug in irritable bowel syndrome.
Latest news
-
China approves Ironwood Pharma’s IBS treatment
Coincides with AZ's Mark Mallon taking over as CEO. Ironwood Pharmaceuticals’ irritable bowel syndrome treatment Linzess has gained approval in China, opening up a market of up to 14m adults ... Approval by China’s NMPA for adults with irritable
-
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use
pain associated with irritable bowel syndrome (IBSs).
-
NHS could save £7bn with greater diagnostics use
The report specifically evaluated the savings of three existing IVD tests - covering suspected heart attacks, pre-eclampsia in pregnancy and diagnosing irritable bowel syndrome (IBS) - if widely used. ... Lastly, IVDs for common bowel condition IBS could
-
Mallinckrodt pays $1.2bn for Sucampo Pharma
Amitizia is the prize asset in the deal, with FDA approvals in hand for three indications - chronic idiopathic constipation as well as constipation linked to irritable bowel syndrome and chronic opioid
-
NICE backs Allergan's IBS therapy Truberzi
NICE has recommended routine NHS funding for Allergan's Truberzi, which is the first drug for irritable bowel syndrome with diarrhoea (IBS-D) to pass through its review process.
More from news
Approximately 0 fully matching, plus 49 partially matching documents found.
Latest Intelligence
-
Erectile dysfunction, constipation, vaginal dryness and other laughing matters
An Irritable Bowel Syndrome campaign tackled the challenge of IBS not being taken seriously by actually using humour. ... This campaign showed doctors suffering from Irritable Disbelief Syndrome (IDS) - a brave move but exactly the perception shift
-
Taking a lean and careful approach
His pioneering research culminated in the drug, Trulance, which has received FDA approval and is being used to treat irritable bowel syndrome and chronic constipation. ... ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
-
Can biosimilars live up to the hype?
She is convinced that biosimilars are essential in treating patients with chronic conditions such as rheumatoid arthritis, irritable bowel syndrome and psoriasis, because they provide the same uplift in quality of
-
Oral biologics delivery still elusive
years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome. ... Among these are Avaxia Biologics, which
-
Pharma deals during April 2014
proteinuria associated with nephrotic syndrome, certain rheumatology-related conditions, and infantile spasms. Whilst this is a 60-year old drug acquired by Questcor in 2001 for $100, 000, generic competition is ... delta opioid receptor antagonist for
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Ironwood appoints Edward Owens to board
irritable bowel syndrome and constipation.
-
Ironwood promotes Dr Mark Currie
Linaclotide was approved as a treatment for irritable bowel syndrome last year by regulators in Europe, where the drug is marketed as Constella by Almirall.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Diagnosing MS: are we getting it right?
MS symptoms can be hard to pin down. I’ve heard bladder issues being attributed to “women’s problems”, bowel issues to irritable bowel syndrome (IBS), and fatigue to stress and
-
World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer
Symptoms of ovarian cancer. The symptoms of ovarian cancer are quite similar to those for less serious conditions such as irritable bowel syndrome or pre-menstrual syndrome [3]. ... Other symptoms include persistent indigestion or nausea, a change in
-
Irritable Bowel Syndrome (IBS) patient insights
Irritable Bowel Syndrome: Patient–Provider Interaction and Patient Education. J Clin Med. 2018; 7(1):3. -----. ... Irritable bowel syndrome in adults: diagnosis and management. NICE Clinical Guideline 61; 2017.
-
IGNIFI
Irritable Bowel Syndrome (IBS) patient insights.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Lilly’s Verzenio scores a win in early-stage breast cancer
- New study identifies drugs that are safe to use in COVID-19 treatment
- Researchers call on Pfizer to delay COVID-19 vaccine application
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Phase 1/2a results for J&J’s COVID-19 vaccine show early promise
- J&J advances COVID-19 vaccine into phase 3 testing
- Covid-19 redefines rules of customer engagement
- Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
- Aurora extends exclusive collaboration with Patient Intelligence Panel (PIP Health)
- Moderna’s COVID-19 vaccine generates strong immune response in older adults
- Regeneron’s COVID-19 antibody cocktail reduces viral load and alleviates symptoms
- What makes a great launch leader and launch team?
PMHub
BOLDSCIENCE
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...
Latest intelligence
- Covid-19 redefines rules of customer engagement
- Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
- Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
- Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
- The concordance conundrum: understanding the complexities of behaviour change
- Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
Quick links
Infographics
